These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 186092)

  • 1. Abnormal fibrin polymerization in liver disease.
    Green G; Thomson JM; Dymock IW; Poller L
    Br J Haematol; 1976 Nov; 34(3):427-39. PubMed ID: 186092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired dysfibrinogenaemia in acute and chronic liver disease.
    Lane DA; Scully MF; Thomas DP; Kakkar VV; Woolf IL; Williams R
    Br J Haematol; 1977 Feb; 35(2):301-8. PubMed ID: 870000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of abnormal fibrin polymerisation with severe liver disease.
    Green G; Poller L; Thomson JM; Dymock IW
    Gut; 1977 Nov; 18(11):909-12. PubMed ID: 590852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired fibrin formation in advanced cirrhosis.
    Dettori AG; Ponari O; Civardi E; Megha A; Pini M; Poti R
    Haemostasis; 1977; 6(2):137-48. PubMed ID: 863294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired dysfibrinogenaemia in liver disease.
    Francis JL; Armstrong DJ
    J Clin Pathol; 1982 Jun; 35(6):667-72. PubMed ID: 7085917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Matsumoto V: a variant with Aalpha19 Arg-->Gly (AGG-->GGG). Comparison between fibrin polymerization stimulated by thrombin or reptilase and fibrin monomer polymerization.
    Tanaka H; Terasawa F; Ito T; Tokunaga S; Ishida F; Kitano K; Kiyosawa K; Okumura N
    Thromb Haemost; 2001 Jan; 85(1):108-13. PubMed ID: 11204560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer.
    Pengo V; Levi Minzi S; Dal Bo Zanon R; Cappellato G; Farinati F; Girolami A
    J Med; 1984; 15(2):149-60. PubMed ID: 6096471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormal fibrin polymerization and its clinical usefulness in patients with chronic liver disease (author's transl)].
    Pengo V; Bertaglia E; Carmignoto F; Schivo P; Guerra C
    Haematologica; 1981 Apr; 66(2):171-80. PubMed ID: 6791993
    [No Abstract]   [Full Text] [Related]  

  • 10. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule.
    Gralnick HR; Givelber H; Abrams E
    N Engl J Med; 1978 Aug; 299(5):221-6. PubMed ID: 207986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemostatic studies on acquired abnormal fibrinogenemia in severe liver diseases and umbilical cord blood].
    Higuchi A
    Hokkaido Igaku Zasshi; 1985 Sep; 60(5):748-62. PubMed ID: 4077019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A naturally occurring antibody that inhibits fibrin polymerization.
    Hoots WK; Carrell NA; Wagner RH; Cooper HA; McDonagh J
    N Engl J Med; 1981 Apr; 304(15):857-61. PubMed ID: 7207522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of serum levels of tryptophan in hepatobiliary disease.
    Yoshida K; Hirayama C
    Clin Chim Acta; 1980 Feb; 101(2-3):235-40. PubMed ID: 6244122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigations on intravascular coagulation in liver disease: souble fibrin monomer complexes in liver cirrhosis.
    Coccheri S; Palareti G; Dalmonte PR; Poggi M; Boggian O
    Haemostasis; 1979; 8(1):8-18. PubMed ID: 378778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies on the polymerization of fibrin monomers in liver disease (author's transl)].
    Narvaiza MJ; Cuesta B; Fernández J; Hernández M; Solana JM; Rocha E
    Sangre (Barc); 1979; 24(4):389-95. PubMed ID: 483116
    [No Abstract]   [Full Text] [Related]  

  • 16. Simulating fibrin clotting time.
    Marx G
    Med Biol Eng Comput; 2006 Mar; 44(1-2):79-85. PubMed ID: 16929924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfibrinogenaemia associated with a defect in the aggregation of the fibrin monomers (Almeria I fibrinogen). A preliminary study.
    Vila V; Regañon E; Fernandez-Pavon A; Aznar J
    Scand J Haematol; 1984 Nov; 33(5):460-5. PubMed ID: 6515329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization.
    Ruf W; Bender A; Lane DA; Preissner KT; Selmayr E; Müller-Berghaus G
    Biochim Biophys Acta; 1988 May; 965(2-3):169-75. PubMed ID: 3365451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings: Abnormal fibrin monomer polymerization in liver disease.
    Green G; Thomson JM; Poller L; Dymock IW
    Gut; 1975 Oct; 16(10):827. PubMed ID: 1205289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.